NCT01218308 - A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children | Biotech Hunter

Enrollment

5,220

Participants

Timeline

Start Date

December 9, 2010

Primary Completion Date

January 9, 2012

Study Completion Date

January 9, 2012

Conditions

Influenza

Interventions

BIOLOGICAL

FluLaval® Quadrivalent

One intramuscular dose for primed subjects. Two intramuscular doses for unprimed subjects.

BIOLOGICAL

Havrix™

Two intramuscular doses for primed subjects. Three intramuscular doses for unprimed subjects.

Trial Locations (12)

GSK Investigational Site, Dhaka

GSK Investigational Site, Adana

GSK Investigational Site, City of Muntinlupa

GSK Investigational Site, Dasmariñas, Cavite

GSK Investigational Site, Ankara

GSK Investigational Site, Bangkok

GSK Investigational Site, Izmir

GSK Investigational Site, Santo Domingo

GSK Investigational Site, Tegucigalpa

GSK Investigational Site, Panama City

GSK Investigational Site, Eskişehir

GSK Investigational Site, Beirut